# **BMJ Open** Median nerve electrical stimulation for restoring consciousness in patients with traumatic brain injury: study protocol for a systematic review and metaanalysis

Ying Yang ,<sup>1,2</sup> Yulan Luo,<sup>1,2</sup> Mei Feng,<sup>3</sup> Ping Luo,<sup>1,2</sup> Jiarong Zeng,<sup>1,2</sup> Xinmao Shi,<sup>1,2</sup> Menglin Tang<sup>4</sup>

# ABSTRACT

To cite: Yang Y, Luo Y, Feng M, et al. Median nerve electrical stimulation for restoring consciousness in patients with traumatic brain injury: study protocol for a systematic review and meta-analysis. BMJ Open 2024;14:e091560. doi:10.1136/ bmjopen-2024-091560

 Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi. org/10.1136/bmjopen-2024-091560).

Received 23 July 2024 Accepted 18 October 2024

#### Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Department of Critical Care Medicine, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China <sup>2</sup>Department of Critical Care Medicine, Sichuan University, Chengdu, China <sup>3</sup>Department of Nursing, Sichuan University, Chengdu, China <sup>4</sup>Department of Cardiovascular Surgery, Sichuan University, Chengdu, China

# **Correspondence to**

Menglin Tang; menglin\_tang@163.com Introduction Traumatic brain injury (TBI) is one of the prevalent critical illnesses encountered in clinical practice, often resulting in a spectrum of consciousness disorders among survivors. Prolonged states of impaired consciousness can significantly elevate the susceptibility to complications such as urinary tract infections and pulmonary issues, consequently leading to a compromised prognosis and substantially impacting the quality of life for affected individuals. Clinical studies have reported that median nerve electrical stimulation (MNES) may have a therapeutic effect in the treatment of disorders of consciousness (DOC). We plan to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of MNES in the management of DOC subsequent to TBI.

Methods and analysis We will conduct a comprehensive literature search in the following electronic databases: Web of Science, Embase, PubMed, Cochrane Library, China Biology Medicine, China National Knowledge Infrastructure, Wan Fang Database and Chinese Scientific Journal Database. The search will be performed from the inception of the databases until 30 September 2024. Furthermore, we will search for relevant ongoing trials in the International Clinical Trial Registry Platform, ClinicalTrials.gov and China Clinical Trial Registry. Grey literature will also be sourced from reputable sources like GreyNet International, Open Grey and Google Scholar. We will include eligible randomised controlled trials. The primary outcome of interest will be the assessment of consciousness disorder severity. To ensure rigour and consistency, two independent reviewers will screen the studies for inclusion, extract relevant data and assess the risk of bias. Any discrepancies will be resolved through discussion or consultation with a third reviewer. The quality of evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Data synthesis and meta-analysis will be conducted using STATA 15.1 software. Ethics and dissemination This systematic review and meta-analysis do not involve the collection or use of any individual patient data, thereby obviating the

necessity for ethical review. The research findings will

- Extendence of the properties of th

brain, potentially resulting in enduring or **B** transitory cognitive, physical and psychological function impairments. Importantly, TBI frequently coincides with changes in consciousness and stands as a substantial contributor to mortality and disability.<sup>12</sup> Every year, 69 million people worldwide suffer from TBI,<sup>3</sup> with a mortality rate of 20%-30%.<sup>4</sup> Furthermore, it is projected to remain the leading cause of neurological disability by

2031,<sup>5</sup> posing a significant public health burden globally. In recent years, progressions in emergency medicine and intensive care technologies have bolstered the survival rates of individuals afflicted by TBI.<sup>6</sup> Nevertheless, many individuals enduring severe TBI may encounter disorders of consciousness (DOC), including coma, vegetative state (vs)/unresponsive wakefulness syndrome and minimally conscious state.<sup>7</sup> Prolonged consciousness disorders not only result in substantial economic burdens but also impart significant mental and emotional strain on the patients' families and society as a whole.<sup>8</sup>

DOC following TBI is associated with widespread functional changes caused by focal brain injury or more comprehensive neural damage<sup>7 9</sup>. This encompasses damage to the brainstem ascending reticular activation system (ARAS), disturbances in neurotransmitters crucial for sustaining the sleep-wake cycle and widespread lesions in the cerebral cortex. Following ARAS injury, pivotal for governing the human sleep-wake cycle, individuals may endure prolonged periods of unconsciousness.<sup>10</sup>

Research has shown that up to 14% of TBI patients experience long-term coma or persistent vs, and the longer the coma duration, the higher the mortality rate.<sup>11 12</sup>The incidence of medical complications in patients with prolonged DOC is high,<sup>13</sup> including muscle tone hyperactivity, sleep disorders, urinary tract infections, hydrocephalus and pneumonia. Such complications can detrimentally influence the rehabilitation trajectory, quality of life and mortality rate.<sup>14 15</sup> Reducing the duration of DOC could potentially enhance outcomes and increase patient participation in rehabilitation therapy.<sup>16</sup> Therefore, identifying methods to expedite the awakening process and reduce the risk of long-term disability in TBI patients with DOC has become a crucial issue in the field of neurological rehabilitation research.

Present treatment strategies aimed at fostering the recuperation of DOC subsequent to TBI include pharmacological interventions, such as amantadine and zolpidem,<sup>17</sup><sup>18</sup> as well as invasive brain stimulation therapies, including vagus nerve stimulation and deep brain stimulation.<sup>19 20</sup> However, current evidence inadequately substantiates the enduring or prolonged efficacy of these therapeutic approaches. Additionally, the potential adverse reactions associated with medications and invasive procedures, such as heightened susceptibility to infections and disease exacerbation,<sup>21 22</sup> curtail their widespread clinical utility, confining them primarily to supplementary roles. In recent years, the exploration of non-invasive stimulation technologies to expedite awakening has garnered attention as a focal point in this domain. As a non-invasive physical therapy method, MNES has been widely used for various nerve-related conditions due to its demonstrated therapeutic benefits.<sup>23 24</sup> Some clinical trials have also reported that MNES may be a potential intervention to accelerate the recovery from DOC following TBI.<sup>25 26</sup> MNES involves the placement of electrodes on the median nerve for electrical stimulation, eliciting central excitatory effects. This process reactivates suppressed neurons and BMJ Open: first published as 10.1136/bmjopen-2024-091560 on 12 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

and

the ARAS, enhances blood perfusion and elevates brainderived neurotrophic factor levels, thereby fostering the awakening process.<sup>27 28</sup>

However, a systematic evaluation of the clinical evidence concerning the effectiveness and safety of MNES in the management of DOC subsequent to TBI is currently absent. This systematic review and meta-analysis aim to provide a comprehensive, evidence-based assessment of the potential benefits and risks of MNES as an intervention for awakening in TBI patients.

# **METHODS**

Protected by copyright, This study will be conducted in strict accordance with the Cochrane Handbook for Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol statement guidelines.<sup>29 30</sup> The study is scheduled to begin on 30 September 2024 and is expected to be completed by 30 June 2025.

#### **Inclusion criteria**

#### Types of studies

including This study will only include randomised controlled trials for without any language or regional restrictions. Non-clinical uses related to text research types, such as cohort studies, purely theoretical studies, case reports, editorials, commentaries, or expert opinions, will be excluded from the analysis.

# Types of participants

The population of interest for this systematic review will be adult patients (aged 18 years and above with no gender restrictions) diagnosed with DOC subsequent to closed TBI.

Patients will be excluded if they exhibit any of the following conditions: unstable vital signs, history of epilepsy, pregnancy, severe arrhythmias or the presence of a pacemaker.

# Types of interventions and comparisons

data mining, AI training The intervention of interest in this study only includes MNES therapy. However, it does not include other forms of stimulation that place electrodes on the right side of the median nerve or both palmar sides, such as elec-Ы troacupuncture and transcutaneous acupoint electrical <u>0</u> stimulation. The specific parameters of the MNES intervention will be no restrictions, including the stimulation intensity, frequency, duration or treatment cycle. The technologies control group will be patients receiving conventional treatment or sham MNES.

# **Types of outcomes**

#### Primary outcomes

The proportion of patients who regained consciousness after 6 months.

#### Secondary outcomes

1. Clinical Checklist Behavior for Evaluating Consciousness Disorders: Glasgow Coma Scale, Coma Recovery Scale-Revised, Wessex Head Injury Matrix and Full Outline of UnResponsiveness (FOUR).

Table 1 Search stratege	gy for PubMed
Sequence	Items
#1	Brain Injuries, Traumatic (MeSH)
#2	Traumatic Brain Injuries
#3	Trauma, Brain
#4	Brain Trauma
#5	Brain Traumas
#6	Traumas, Brain
#7	Traumatic Brain Injury
#8	Encephalopathy, Traumatic
#9	Encephalopathies, Traumatic
#10	Traumatic Encephalopathies
#11	Injury, Brain, Traumatic
#12	Traumatic Encephalopathy
#13	ТВІ
#14	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#15	Coma (MeSH)
#16	Comas
#17	Comatose
#18	Consciousness Disorders (MeSH)
#19	Consciousness Disorder
#20	Disorder of Consciousness
#21	Disorders of Consciousness
#22	Consciousness, Level Depressed
#23	Depressed Level of Consciousness
#24	Consciousness, Level Altered
#25	Altered Level of Consciousness
#26	Semiconsciousness
#27	#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26
#28	Electric Stimulation Therapy (MeSH)
#29	Therapy, Electric Stimulation
#30	Stimulation Therapy, Electric
#31	Electrotherapy
#32	Therapeutic Electric Stimulation
#33	Electric Stimulation, Therapeutic
#34	Stimulation, Therapeutic Electric
#35	Electrical Stimulation Therapy
#36	Stimulation Therapy, Electrical
#37	Therapy, Electrical Stimulation
#38	Therapeutic Electrical Stimulation
#39	Electrical Stimulation, Therapeutic
#40	Stimulation, Therapeutic Electrical
#41	Interferential Current Electrotherapy
	Continued

l trair

S

2. Disability Rating Scale (DRS).

3. Incidence of complications.

4. Electrophysiological and neuroimaging evaluation.

5. Incidence of adverse events.

# Information sources

Table 1

#42

#43

#44

#45

#46

#47

#48

#49

#50

#51 #52

#53

#54

#55

Sequence

Continued

Items

Current

Stimulation

#44 OR #45

Randomized Random

Placebo

Groups

Trial

Electroacupuncture

Clinical trials (MeSH)

#51 OR #52 OR #53

Randomized Clinical trials

#47 OR #48 OR #49 OR #50 OR

#14 AND #27 AND #46 AND #54

Electrotherapy, Interferential

Transcutaneous Electric Nerve

Median nerve electrical stimulation

#28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR

# Electronic databases

Protected by copyright, including for uses related to text and data mining, A We will conduct a comprehensive literature search in the following electronic databases: Web of Science, Embase, PubMed, Cochrane Library, China Biology Medicine, China National Knowledge Infrastructure, Wan Fang Database and Chinese Scientific Journal Database. The search will encompass the databases from their inception to 30 September 2024. Furthermore, we will manually scrutinise the reference lists of the retrieved articles to identify any potentially eligible studies. No constraints will be imposed on language or publication status. Other resources In addition to the electronic database searches, we will **g** 

comprehensively explore clinical trial registration platforms to pinpoint any ongoing or unpublished trials relevant to our review. These platforms will include the WHO's International Clinical Trial Registration Platform, ClinicalTrials.gov, the Chinese Clinical Trial Registry and the Cochrane Central Register of Controlled Trials. Furthermore, we will search for valuable grey literature through specialised websites, such as GreyNet International, OpenGrey and Google Scholar. This methodology aims to uncover additional relevant studies that




Figure 1 Flow diagram of the study selection process. MNS, median nerve electrical stimulation.

may not have been published in the peer-reviewed literature, thereby reducing the risk of publication bias and enhancing the completeness of our systematic review.

# Search strategy

To ensure the rigour and accuracy of the literature search, we will construct a comprehensive search strategy based on the Patient, Intervention, Comparison, Outcome, Study design (PICOS) framework. This strategy will incorporate subject-specific keywords and free-text terms to encompass all relevant studies. As an example, the detailed search strategy for the PubMed database is presented in table 1.

# **Selection of studies**

Two independent researchers will initially screen the titles and abstracts of the retrieved literature to exclude irrelevant studies. Subsequently, they will then thoroughly review the full-text articles to determine eligibility based on the predefined inclusion and exclusion criteria. Any disagreements will be discussed and resolved with the third researcher. The selection process is shown in figure 1.

# **Data extraction**

Two independent research teams will extract data from the included studies using a pre-designed data extraction table. The information to be collected will include the first author, publication year, nationality, sample size of experimental and control groups, participant characteristics (age, gender, comorbidities, etc.), details of the intervention (stimulation parameters, treatment duration and course) and outcome measures (consciousness assessment scales, disability rating scales, reported adverse events, etc.). The data extraction process will be independently carried out by the two research teams. Any discrepancies or disagreements arising during this phase will be resolved through discussion and consultation with a third researcher if necessary.

# **Risk of bias assessment**

The risk of bias assessment for the included studies will be conducted based on the Cochrane Systematic Review Manual (V.5.1.0). The following key domains will be evaluated: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, completeness of outcome data, selective reporting and other potential sources of bias. Each domain will be judged as having a low risk of bias, an unclear risk of bias or a high risk of bias, according to the predefined criteria outlined in the Cochrane Handbook. Any disagreements will be discussed and resolved with the third researcher.

# **Data synthesis**

The data analysis will be conducted using Stata V.15.0. For continuous data, we will use the standardised mean

difference (SMD) and 95% CI to quantify the effect sizes. For dichotomous data, we will calculate the OR and 95% CI to estimate the treatment effects. Statistical significance will be determined based on whether the 95% CI of the SMD does not include 0 or the 95% CI of the OR does not include 1. If the 95% CI does not encompass these values, the difference will be considered statistically significant.

# Assessment of heterogeneity

The assessment of heterogeneity will be conducted using the I<sup>2</sup> statistic. If the P < 50% with the p>0.1, the heterogeneity across the included studies will be considered low. In such cases, a fixed-effects model will be used to perform the meta-analysis calculations. However, if the P > 50% or p<0.1, significant heterogeneity will be present. In this scenario, sensitivity analyses and subgroup analyses will be performed to explore the potential sources of heterogeneity. If the subgroup analyses are unable to adequately address the observed heterogeneity, a random-effects model will be used for the meta-analysis calculations.

# **Sensitivity analysis**

To assess the robustness of the meta-analysis results, we will conduct a sensitivity analysis by sequentially removing each study from the analysis and re-estimating the overall effect size.

# **Subgroup analysis**

If the sensitivity analysis fails to adequately explain the observed heterogeneity, we will conduct subgroup analyses to explore the potential sources of variability. The subgroup analyses will be based on the following study-level characteristics: severity of traumatic brain injury, gender of participants, age of participants, presence of comorbidities, frequency, intensity, duration and treatment cycle of MNES.

# Assessment of publication bias

To assess the potential presence of publication bias, we will conduct Egger's linear regression test and Begg's rank correlation test. If the results of these analyses suggest the presence of publication bias, we will further explore its potential impact using the trim and fill method.

# **Summary of evidence**

The quality of the evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. This will be independently completed by two researchers, and any disagreements will be resolved through discussion or by consulting a third researcher.

# **ETHICS AND DISSEMINATION**

This study will not involve the collection or analysis of any individual patient data and therefore does not raise any ethical concerns related to the protection of personal privacy. As this study is based solely on the synthesis of published literature, no formal ethical review is required. The results of the study will be published in peer-reviewed journals.

**Contributors** YY and YL designed this study. MT served as the supervisor of this study. The research strategy for each database was designed by all review authors. YY and PL independently carried out the search, selection and identification of studies and the data extraction. YL and MF performed the data synthesis and analysis. JZ served as the third author for the settlement of the disagreement. XS and MT were the advisers for methodology. All authors have approved the publication of this study protocol. YY is the guarantor.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### ORCID iD

Ying Yang http://orcid.org/0009-0009-1932-6960

# REFERENCES

- 1 Giacino JT, Trott CT. Rehabilitative management of patients with disorders of consciousness: grand rounds. *J Head Trauma Rehabil* 2004;19:254–65.
- 2 Feigin VL, Theadom A, Barker-Collo S, et al. Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol 2013;12:53–64.
- 3 Dewan MC, Rattani A, Gupta S, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg 2019;130:1080–97.
- 4 Ye Z, Li Z, Zhong S, et al. The recent two decades of traumatic brain injury: a bibliometric analysis and systematic review. Int J Surg 2024;110:3745–59.
- 5 Maas AIR, Menon DK, Adelson PD, *et al*. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017;16:987–1048.
- 6 Stocchetti N, Carbonara M, Citerio G, et al. Severe traumatic brain injury: targeted management in the intensive care unit. Lancet Neurol 2017;16:452–64.
- 7 Giacino JT, Fins JJ, Laureys S, *et al.* Disorders of consciousness after acquired brain injury: the state of the science. *Nat Rev Neurol* 2014;10:99–114.
- 8 Zarshenas S, Colantonio A, Horn SD, *et al.* Cognitive and Motor Recovery and Predictors of Long-Term Outcome in Patients With Traumatic Brain Injury. *Arch Phys Med Rehabil* 2019;100:1274–82.
- 9 Adams JH, Jennett B, McLellan DR, et al. The neuropathology of the vegetative state after head injury. J Clin Pathol 1999;52:804–6.
- 10 Machado C, Estevez M, Redriguez R, et al. Wakefulness and loss of awareness: brain and brainstem interaction in the vegetative state. *Neurology (ECronicon)* 2010;75:751; .
- 11 Andriessen TMJC, Horn J, Franschman G, et al. Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J Neurotrauma 2011;28:2019–31.
- 12 Li Y, Gu J, Zhou J, et al. The epidemiology of traumatic brain injury in civilian inpatients of Chinese Military Hospitals, 2001-2007. *Brain Inj* 2015;29:981–8.
- 13 Nakase-Richardson R, Tran J, Cifu D, et al. Do rehospitalization rates differ among injury severity levels in the NIDRR Traumatic Brain Injury Model Systems program? Arch Phys Med Rehabil 2013;94:1884–90.
- 14 Ganesh S, Guernon A, Chalcraft L, et al. Medical comorbidities in disorders of consciousness patients and their association with functional outcomes. *Arch Phys Med Rehabil* 2013;94:1899–907.
- 15 Whyte J, Nakase-Richardson R. Disorders of Consciousness: Outcomes, Comorbidities, and Care Needs. Arch Phys Med Rehabil 2013;94:1851–4.

# **Open access**

- 16 Whyte J, Nordenbo AM, Kalmar K, et al. Medical complications during inpatient rehabilitation among patients with traumatic disorders of consciousness. Arch Phys Med Rehabil 2013;94:1877–83.
- 17 Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012;366:819–26.
- 18 Chatelle C, Thibaut A, Gosseries O, et al. Changes in cerebral metabolism in patients with a minimally conscious state responding to zolpidem. *Front Hum Neurosci* 2014;8:917.
- 19 Corazzol M, Lio G, Lefevre A, et al. Restoring consciousness with vagus nerve stimulation. Curr Biol 2017;27:R994–6.
- 20 Schiff ND, Giacino JT, Kalmar K, et al. Behavioural improvements with thalamic stimulation after severe traumatic brain injury. *Nature New Biol* 2007;448:600–3.
- 21 Nickels JL, Schneider WN, Dombovy ML, et al. Clinical use of amantadine in brain injury rehabilitation. Brain Inj 1994;8:709–18.
- 22 Thibaut A, Schiff N, Giacino J, et al. Therapeutic interventions in patients with prolonged disorders of consciousness. *Lancet Neurol* 2019;18:600–14.
- 23 Zhou Y, Yang H, You M, et al. Cognition-Enhancement Effect of Median Nerve Electrical Stimulation in Patients with Cognitive Impairment: A Retrospective Cohort Study. *World Neurosurg* 2024;184:e537–45.

- 24 Tsai S-T, Chuang W-Y, Kuo C-C, *et al.* Dorsolateral subthalamic neuronal activity enhanced by median nerve stimulation characterizes Parkinson's disease during deep brain stimulation with general anesthesia. *J Neurosurg* 2015;123:1394–400.
- 25 Wu X, Xie L, Lei J, *et al.* Acute traumatic coma awakening by right median nerve electrical stimulation: a randomised controlled trial. *Intensive Care Med* 2023;49:633–44.
- 26 Lei J, Wang L, Gao G, *et al*. Right Median Nerve Electrical Stimulation for Acute Traumatic Coma Patients. *J Neurotrauma* 2015;32:1584–9.
- 27 Edlow BL, Sanz LRD, Polizzotto L, et al. Therapies to Restore Consciousness in Patients with Severe Brain Injuries: A Gap Analysis and Future Directions. *Neurocrit Care* 2021;35:68–85.
- 28 Liu JT, Wang CH, Chou IC, *et al.* Regaining consciousness for prolonged comatose patients with right median nerve stimulation. *Acta Neurochir* 2003;87:11–4.
- 29 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2016;354:i4086.
- 30 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.